» Articles » PMID: 25763403

Comparison of IVF Outcomes Between Minimal Stimulation and High-Dose Stimulation for Patients with Poor Ovarian Reserve

Overview
Publisher Wiley
Date 2015 Mar 13
PMID 25763403
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

We examined whether treatment with minimum-dose stimulation (MS) protocol enhances clinical pregnancy rates compared to high-dose stimulation (HS) protocol. A retrospective cohort study was performed comparing IVF and pregnancy outcomes between MS and HS gonadotropin-antagonist protocol for patients with poor ovarian reserve (POR). Inclusion criteria included patients with an anti-Müllerian hormone (AMH) ≤8 pmol/L and/or antral follicle count (AFC) ≤5 on days 2-3 of the cycle. Patients from 2008 exclusively had a HS protocol treatment, while patients in 2010 had treatment with a MS protocol exclusively. The MS protocol involved letrozole at 2.5 mg over 5 days, starting from day 2, overlapping with gonadotropins, starting from the third day of letrozole at 150 units daily. GnRH antagonist was introduced once one or more follicles reached 14 mm or larger. The HS group received gonadotropins (≥300 IU/day) throughout their antagonist cycle. Clinical pregnancy rate was significantly higher in the MS protocol compared to the HS protocol (P = 0.007). Furthermore, the live birth rate was significantly higher in the MS group compare to the HS group (P = 0.034). In conclusion, the MS IVF protocol is less expensive (lower gonadotropin dosage) and resulted in a higher clinical pregnancy rate and live birth rate than a HS protocol for poor responders.

Citing Articles

Impact of letrozole co-treatment in an antagonist protocol for IVF/ICSI: a retrospective study.

Lin J, Wu F, Wang B, Zhu Q, Lin J Reprod Biol Endocrinol. 2024; 22(1):126.

PMID: 39415184 PMC: 11481315. DOI: 10.1186/s12958-024-01297-5.


Letrozole co-treatment in an antagonist protocol for overweight women undergoing IVF treatment: a retrospective study.

Lin J, Wu F, Zhu Y, Wang B, Cao Z, Lin J BMC Pregnancy Childbirth. 2024; 24(1):592.

PMID: 39256667 PMC: 11386352. DOI: 10.1186/s12884-024-06795-3.


The Efficacy of Letrozole Co-Treatment in an Antagonist Protocol for Women with Polycystic Ovary Syndrome Undergoing IVF: A Retrospective Study.

Lin J, Wu F, Zhu Y, Zhu Q, Du T, Lin J Drug Des Devel Ther. 2024; 18:2823-2835.

PMID: 39006189 PMC: 11244072. DOI: 10.2147/DDDT.S458608.


Comparison Fertilization Outcomes between DouStim and Minimal Stimulation Protocols in Poor Ovarian Responders: A Randomized Clinical Trial.

Saharkhiz N, Salehpoor S, Hosseini S, Nazari L, Sheibani S, Doohandeh T Int J Fertil Steril. 2024; 18(2):135-139.

PMID: 38368516 PMC: 10875315. DOI: 10.22074/ijfs.2023.552687.1293.


Insulin-like growth factor binding protein-1 and insulin in polycystic ovary syndrome: a systematic review and meta-analysis.

Jin Y, Sun F, Yang A, Yu X, Li Y, Liang S Front Endocrinol (Lausanne). 2024; 14:1279717.

PMID: 38174331 PMC: 10762309. DOI: 10.3389/fendo.2023.1279717.


References
1.
Gleicher N, Barad D . Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol. 2011; 9:67. PMC: 3112409. DOI: 10.1186/1477-7827-9-67. View

2.
Vollenhoven B, Osianlis T, Catt J . Is there an ideal stimulation regimen for IVF for poor responders and does it change with age?. J Assist Reprod Genet. 2008; 25(11-12):523-9. PMC: 2593772. DOI: 10.1007/s10815-008-9274-6. View

3.
Mutlu M, Erdem M, Erdem A, Yildiz S, Mutlu I, Arisoy O . Antral follicle count determines poor ovarian response better than anti-Müllerian hormone but age is the only predictor for live birth in in vitro fertilization cycles. J Assist Reprod Genet. 2013; 30(5):657-65. PMC: 3663963. DOI: 10.1007/s10815-013-9975-3. View

4.
Weil S, Vendola K, Zhou J, Bondy C . Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab. 1999; 84(8):2951-6. DOI: 10.1210/jcem.84.8.5929. View

5.
Nikolaou D, Templeton A . Early ovarian ageing: a hypothesis. Detection and clinical relevance. Hum Reprod. 2003; 18(6):1137-9. DOI: 10.1093/humrep/deg245. View